Cargando…
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
The PD-1:PD-L1 immune checkpoint axis is central in the escape of cancer cells from anticancer immune responses. Monoclonal antibodies (mAbs) specific for PD-L1 have been approved for treatment of various cancer types. Although PD-L1 blockade has proven its merit, there are still several aspects tha...
Autores principales: | Broos, Katrijn, Lecocq, Quentin, Xavier, Catarina, Bridoux, Jessica, Nguyen, Tham T., Corthals, Jurgen, Schoonooghe, Steve, Lion, Eva, Raes, Geert, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628009/ https://www.ncbi.nlm.nih.gov/pubmed/31234464 http://dx.doi.org/10.3390/cancers11060872 |
Ejemplares similares
-
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018) -
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
por: Broos, Katrijn, et al.
Publicado: (2017) -
Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production
por: Broos, Katrijn, et al.
Publicado: (2019) -
Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020) -
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
por: Chigoho, Dora Mugoli, et al.
Publicado: (2021)